GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Genetic Technologies Corp (NAS:AGTC) » Definitions » Pre-Tax Income

Applied Genetic Technologies (Applied Genetic Technologies) Pre-Tax Income : $-70.07 Mil (TTM As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Applied Genetic Technologies Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Applied Genetic Technologies's pretax income for the three months ended in Sep. 2022 was $-18.41 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2022 was $-70.07 Mil. Applied Genetic Technologies's pretax margin was %.

During the past 11 years, Applied Genetic Technologies's highest Pretax Margin was 7.11%. The lowest was -21560.62%. And the median was -781.39%.


Applied Genetic Technologies Pre-Tax Income Historical Data

The historical data trend for Applied Genetic Technologies's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Genetic Technologies Pre-Tax Income Chart

Applied Genetic Technologies Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.21 -1.90 -45.76 -59.84 -68.75

Applied Genetic Technologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.12 -19.11 -14.24 -18.31 -18.41

Competitive Comparison of Applied Genetic Technologies's Pre-Tax Income

For the Biotechnology subindustry, Applied Genetic Technologies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Genetic Technologies's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Applied Genetic Technologies's Pre-Tax Income falls into.



Applied Genetic Technologies Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Applied Genetic Technologies's Pretax Income for the fiscal year that ended in Jun. 2022 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-66.175+0.099+-2.674+0+0
=-68.75

Applied Genetic Technologies's Pretax Income for the quarter that ended in Sep. 2022 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-17.344+-0.409+-0.657+0+0
=-18.41

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Genetic Technologies  (NAS:AGTC) Pre-Tax Income Explanation

Applied Genetic Technologies's Pretax Margin for the quarter that ended in Sep. 2022 is calculated as

Pretax Margin=Pretax Income/Revenue
=-18.41/0
=%

During the past 11 years, Applied Genetic Technologies's highest Pretax Margin was 7.11%. The lowest was -21560.62%. And the median was -781.39%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Genetic Technologies Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Applied Genetic Technologies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Genetic Technologies (Applied Genetic Technologies) Business Description

Traded in Other Exchanges
N/A
Address
14193 NW 119th Terrace, Suite 10, Alachua, FL, USA, 32615
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Executives
Susan Schneider officer: Chief Medical Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Jonathan I Lieber officer: Chief Financial Officer C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Stephen W Potter officer: See Remarks 7015 ALBERT EINSTEIN DR, COLUMBIA MD 21046
Gerald Anthony Reynolds officer: Chief Accounting Officer C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Susan B. Washer director, officer: President and CEO C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Hope Doyley-gay officer: General Counsel C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Abraham Scaria officer: Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Yehia Hashad director C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Krol Patrick Johan Hendrik 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Privium Fund Management B.v. 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Aescap 2.0 Stichting 10 percent owner GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Inspirational Visions B.v. 10 percent owner C/O PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, 2333 CK LEIDEN P7 2333
Brian Krex officer: General Counsel C/O AGTC, 14193 NW 119TH TERRACE, SUITE #10, ALACHUA FL 32615